AP1S1 and neoplasm: Upregulation of adaptor-related protein complex 1 subunit sigma 1 (AP1S1), for instance, leads to matrix stiffness and resistance to erlotinib.719 Chen et al. extensively reviewed the tumor microenvironmental changes following tyrosine kinase inhibitor therapies, a detailed description of these is out of the scope of our paper.720